Literature DB >> 16847078

Cardiac and clinical phenotype in Barth syndrome.

Carolyn T Spencer1, Randall M Bryant, Jane Day, Iris L Gonzalez, Steven D Colan, W Reid Thompson, Julie Berthy, Sharon P Redfearn, Barry J Byrne.   

Abstract

OBJECTIVE: Barth syndrome, an X-linked disorder that is characterized by cardiomyopathy, neutropenia, skeletal myopathy, and growth delay, is caused by mutations in the taffazin gene at Xq28 that result in cardiolipin deficiency and abnormal mitochondria. The clinical phenotype in Barth syndrome has not been characterized systematically, and the condition may be underrecognized. We sought to evaluate extent of cardioskeletal myopathy, potential for arrhythmia, delays in growth, and biochemical correlates of disease severity in patients with this disorder.
METHODS: We conducted an observational, cross-sectional study of the largest cohort of patients with Barth syndrome to date (n = 34; age range: 1.2-22.6 years). Evaluation included echocardiography, electrocardiography (standard and signal-averaged), microvolt T wave alternans analysis, biochemical and hematologic laboratory analyses, and physical therapy evaluation of skeletal myopathy.
RESULTS: Family history was positive for confirmed or suspected Barth syndrome in 63%. Ninety percent of patients had a clinical history of cardiomyopathy (mean age at diagnosis of cardiomyopathy: 5.5 months; at genetic confirmation of Barth syndrome: 4.6 years). Echocardiography revealed a mean ejection fraction of 50% +/- 10%, mean fractional shortening of 28% +/- 5%, and mean left ventricular end-diastolic volume z score of 1.9 +/- 1.8. Left ventricular morphology demonstrated increased trabeculations or true noncompaction in 53%. Of 16 patients who were evaluated at > or = 11 years of age, 7 (43%) had documented ventricular arrhythmia. Growth deficiency was present (mean weight percentile: 15%; mean height percentile: 8%). Laboratory analysis revealed low total white blood cell count (absolute count: < 4000 cells per microL) in 25% of those who were not on granulocyte colony-stimulating factor. Hypocholesterolemia was present in 24%, decreased low-density lipoprotein cholesterol in 56%, low prealbumin in 79%, and mildly elevated creatine kinase in 15%.
CONCLUSIONS: Our cohort demonstrated clinical variability, but most had cardiomyopathy and diminished growth velocity, with a propensity toward neutropenia and low cholesterol. There was increased incidence of ventricular arrhythmia, predominantly in adolescents and young adults. Barth syndrome should be considered when boys present with cardiomyopathy, especially when associated with increased left ventricular trabeculations, neutropenia, skeletal muscle weakness, or family history indicating an X-linked pattern of inheritance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847078     DOI: 10.1542/peds.2005-2667

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  90 in total

1.  Barth syndrome diagnosed in the subclinical stage of heart failure based on the presence of lipid storage myopathy and isolated noncompaction of the ventricular myocardium.

Authors:  Atsuhito Takeda; Akira Sudo; Masafumi Yamada; Hirokuni Yamazawa; Gaku Izumi; Ichizo Nishino; Tadashi Ariga
Journal:  Eur J Pediatr       Date:  2011-09-20       Impact factor: 3.183

2.  Skeletal muscle mitochondrial function is associated with longitudinal growth velocity in children and adolescents.

Authors:  Shana E McCormack; Meaghan A McCarthy; Loredana Farilla; Mirko I Hrovat; David M Systrom; Steven K Grinspoon; Amy Fleischman
Journal:  J Clin Endocrinol Metab       Date:  2011-08-10       Impact factor: 5.958

Review 3.  Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases.

Authors:  Harjot K Saini-Chohan; Ryan W Mitchell; Frédéric M Vaz; Teresa Zelinski; Grant M Hatch
Journal:  J Lipid Res       Date:  2011-11-07       Impact factor: 5.922

4.  Characterization of a transgenic short hairpin RNA-induced murine model of Tafazzin deficiency.

Authors:  Meghan S Soustek; Darin J Falk; Cathryn S Mah; Matthew J Toth; Michael Schlame; Alfred S Lewin; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2011-05-19       Impact factor: 5.695

5.  Congenic mice confirm that collagen X is required for proper hematopoietic development.

Authors:  Elizabeth Sweeney; Douglas Roberts; Tina Corbo; Olena Jacenko
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

Review 6.  Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.

Authors:  Hana M Zegallai; Grant M Hatch
Journal:  Mol Cell Biochem       Date:  2021-01-07       Impact factor: 3.396

7.  Left ventricular noncompaction cardiomyopathy in Barth syndrome: an example of an undulating cardiac phenotype necessitating mechanical circulatory support as a bridge to transplantation.

Authors:  Samuel P Hanke; Aimee B Gardner; John P Lombardi; Peter B Manning; David P Nelson; Jeffrey A Towbin; John L Jefferies; Angela Lorts
Journal:  Pediatr Cardiol       Date:  2012-03-17       Impact factor: 1.655

8.  Intrafamilial variability for novel TAZ gene mutation: Barth syndrome with dilated cardiomyopathy and heart failure in an infant and left ventricular noncompaction in his great-uncle.

Authors:  Diti Ronvelia; Jaclyn Greenwood; Julia Platt; Simin Hakim; Michael V Zaragoza
Journal:  Mol Genet Metab       Date:  2012-09-18       Impact factor: 4.797

9.  AAV-Mediated TAZ Gene Replacement Restores Mitochondrial and Cardioskeletal Function in Barth Syndrome.

Authors:  Silveli Suzuki-Hatano; Madhurima Saha; Skylar A Rizzo; Rachael L Witko; Bennett J Gosiker; Manashwi Ramanathan; Meghan S Soustek; Michael D Jones; Peter B Kang; Barry J Byrne; W Todd Cade; Christina A Pacak
Journal:  Hum Gene Ther       Date:  2018-10-03       Impact factor: 5.695

Review 10.  Cardiogenetics, neurogenetics, and pathogenetics of left ventricular hypertrabeculation/noncompaction.

Authors:  Josef Finsterer
Journal:  Pediatr Cardiol       Date:  2009-01-29       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.